Acute and chronic effects of oral genistein administration in neonatal mice.

Soy-based infant formulas are widely used in the United States and some other countries. These formulas contain high levels of the estrogenic isoflavone genistein, leading to concern that neonatal genistein exposure could cause acute and/or long-term adverse effects on reproductive and other organs. However, previous work to assess genistein effects in rodent models has not typically replicated the route of delivery and/or serum genistein concentrations reported for soy formula-fed human infants. Our objective was to develop a mouse model that more closely mimics the oral genistein exposure and total serum genistein concentrations observed in soy formula-fed infants. Mouse pups were dosed orally with genistein in a soy formula-corn oil emulsion from Postnatal Day (PND) 1 to PND 5, then effects on reproductive and non-reproductive organs were assessed after dosing and during subsequent development. Neonatal treatment resulted in changes both at the completion of dosing (PND 5) and in adult animals. At PND 5, neonatal genistein treatment caused increased relative uterine weight and down-regulation of progesterone receptor in uterine epithelia. Estrogenic effects of genistein were also seen in the neonatal ovary and thymus, which had an increase in the incidence of multioocyte follicles (MOFs) and a decrease in thymic weight relative to body weight, respectively. The increased incidence of MOFs persisted into adulthood for neonatally treated genistein females, and estrous cycle abnormalities were seen at 6 mo of age despite normal fertility in these mice. The immediate and long-term effects in this neonatal animal model raise concerns that high serum concentrations of genistein are estrogenic and could potentially impact the development of human infants fed soy formula.

The F box protein S phase kinase-associated protein 2 regulates adipose mass and adipocyte number in vivo.

OBJECTIVE: The etiology of some obesity may involve adipocyte hyperplasia. However, the role of adipocyte number in establishing adipose mass is unclear. Cyclin-dependent kinase inhibitor p27 regulates activity of cyclin/cyclin-dependent kinase complexes responsible for cell cycle progression. This protein is critical for establishing adult adipocyte number, and p27 knockout increases adult adipocyte number. The SCF (for Skp1-Cullin-F-box protein) complex targets proteins such as p27 for ubiquitin-proteosome degradation; the F box protein S phase kinase-associated protein 2 (Skp2), a component of the SCF complex, specifically recognizes p27 for degradation. We used Skp2 knockout (Skp2(-/-)) mice to test whether Skp2 loss decreased adipose mass and adipocyte number. RESEARCH METHODS AND PROCEDURES: We measured body weight, adipose mass, adipocyte diameter and number, and glucose tolerance in wild-type (WT), Skp2(-/-), and p27(-/-)Skp2(-/-) mice. Mouse embryo fibroblasts (MEFs) from WT and Skp2(-/-) fetuses were differentiated to determine whether Skp2 directly affected adipogenesis. RESULTS: Skp2(-/-) mice had a 50% decrease in both subcutaneous and visceral fat pad mass and adipocyte number; these decreases exceeded those in body weight, kidney, or muscle. To test the hypothesis that Skp2 effects on adipocyte number involved p27 accumulation, we used p27(-/-)Skp2(-/-) double knockout mice. The Skp2(-/-) decrements in adipocyte number and fat pad mass were totally reversed in p27(-/-)Skp2(-/-) mice. Adipogenesis was inhibited in MEFs from Skp2(-/-) vs. WT mice, and this inhibition was absent in MEFs from p27(-/-)Skp2(-/-) mice. DISCUSSION: Our results indicate that Skp2 regulates adipogenesis and ultimate adipocyte number in vivo; thus, Skp2 may contribute to obesity involving adipocyte hyperplasia.

Microarray analysis of early adipogenesis in C3H10T1/2 cells: cooperative inhibitory effects of growth factors and 2,3,7,8-tetrachlorodibenzo-p-dioxin.

C3H10T1/2 mouse embryo fibroblasts differentiate into adipocytes when stimulated by a standard hormonal mixture (IDMB). 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), via the aryl hydrocarbon receptor (AhR), inhibits induction of the key adipogenic gene peroxisome proliferator-activated receptor gamma (PPARgamma) and subsequent adipogenesis. This TCDD-mediated inhibition requires activation of the extracellular signal-regulated kinase (ERK) pathway, which can be accomplished by serum, epidermal growth factor (EGF), or fibroblast growth factor (FGF). In the absence of serum or growth factors, IDMB induced adipogenesis without mitosis. Microarray analysis identified 200 genes that exhibited expression changes of at least twofold after 24 h of IDMB treatment. This time precedes most PPARgamma stimulation but follows the period of TCDD/ERK cooperation and periods of increased cell contraction and DNA synthesis. Functionally related gene clusters include genes associated with cell structure, triglyceride and cholesterol metabolism, oxidative regulation, and secreted proteins. In the absence of growth factors TCDD inhibited 30% of these IDMB responses without inhibiting the process of differentiation. A combination of EGF and TCDD that blocks differentiation cooperatively blocked a further 44 IDMB-responsive genes, most of which have functional links to differentiation, including PPARgamma. Cell cycle regulators that are stimulated by EGF were substantially inhibited by IDMB but these responses were unaffected by TCDD. By contrast, TCDD and EGF cooperatively reversed IDMB-induced changes in cell adhesion complexes immediately prior to increases in PPARgamma1 expression. Changes in adhesion-linked signaling may play a key role in TCDD affects on differentiation.

TCDD administration after the pro-adipogenic differentiation stimulus inhibits PPARgamma through a MEK-dependent process but less effectively suppresses adipogenesis.

Hormone (IDMB)-induced adipogenesis in C3H10T1/2 cells is suppressed by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) via the aryl hydrocarbon receptor (AhR). We have previously reported that TCDD addition 48 h before the hormonal stimulation of IDMB suppresses a key mediator of adipogenesis, the peroxisome proliferator-activated receptor (PPARgamma), by a MEK/ERK dependent mechanism. Here we add to previous evidence that this synergism functions after IDMB addition but before increased PPARgamma1 transcription. Suppression remains effective and MEK/ERK dependent when TCDD is added 6-12 h after IDMB addition but not when delayed to 16-24 h, thus preceding the rise in PPARgamma mRNA. TCDD suppression of the number of committed adipocytes and of triglyceride formation is less effective with the delayed addition. TCDD therefore does not directly suppress the expression of the key mediator PPARgamma1. An alternative mediation of adipocyte commitment is apparently less sensitive to the 6-12 h of delayed TCDD addition. TCDD suppression potencies (EC(50) = 50 pM) match the potencies for stimulation of CYP1B1 protein and AhR-sensitive reporters. The AhR antagonist 3'-methoxy-4'-nitroflavone (3-MNF) inhibited both TCDD-mediated CYP1B1 induction and inhibition of PPARgamma protein expression. This antagonism was only effective when 3-MNF was present in the 24-h period after IDMB addition. TCDD activation of AhR in conjunction with MEK/ERK therefore generates PPARgamma1 suppression activity before the increase of PPARgamma1 synthesis. The potency and inhibition data are consistent with induction of one or more gene products that sustain suppression through the extended period of PPARgamma1 transcription.